Logo

BMS Reports Results of Opdivo (nivolumab) + Yervoy (ipilimumab) in P-III (CheckMate -901) Trial as 1L Treatment for Unresectable or Metastatic Urothelial Carcinoma

Share this

BMS Reports Results of Opdivo (nivolumab) + Yervoy (ipilimumab) in P-III (CheckMate -901) Trial as 1L Treatment for Unresectable or Metastatic Urothelial Carcinoma

Shots:

  • The P-III (CheckMate -901) trial evaluates Opdivo (1mg/kg) + Yervoy (3mg/kg, q3w for 4 cycles) or Opdivo (480mg, q4w) + CT vs CT alone in 707 patients with untreated unresectable or metastatic UC who are ineligible for cisplatin-based CT
  • The trial failed to meet the 2EPs of OS in patients whose tumor cells express PD-L1 ≥1% at the final analysis, no new safety signals were identified. Following the IDMC’s recommendation, the trial continues to evaluate other 1EPs & 2EPs
  • The primary & sub-studies for the (CheckMate -901) trial are still ongoing & the company will provide additional results shortly. Opdivo + Yervoy showed improvements in OS in 6 P-III trials for NSCLC, MM, RCC, MPM & ESCC

Ref: BMS | Image: BMS

Click here to­ read the full press release 

Senior Editor

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions